Pulmonary endothelium-derived PD-L1 induced by the H9N2 avian influenza virus inhibits the immune response of T cells.
Animals
B7-H1 Antigen
/ genetics
Cells, Cultured
Endothelial Cells
/ immunology
Influenza A Virus, H9N2 Subtype
/ immunology
Interferon-gamma
/ immunology
Lung
/ cytology
Microvessels
/ cytology
Rats
Specific Pathogen-Free Organisms
T-Lymphocytes
/ immunology
Tumor Necrosis Factor-alpha
/ immunology
Up-Regulation
Virus Replication
H9N2 virus
PD-L1
Primary microvascular endothelial cells
T cell immune response
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
received:
24
11
2019
accepted:
10
05
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
10
4
2021
Statut:
epublish
Résumé
The PD-1/PD-L1 pathway is an inhibitory signaling pathway that maintains the balance between the immune response and immunotolerance, and its overactivation in cancer and viral infections inhibits T cell function. The target cells of various viruses, microvascular endothelial cells (MECs) have been shown to be key regulatory points in immune regulation and virion diffusion in vivo during infection with multiple influenza virus subtypes. Furthermore, avian influenza virus (AIV) infection can induce immunosuppression by causing imbalances in immune responses and immune organ damage. Thus, the aim of this study was to investigate whether the H9N2 virus inhibited the immune function of T cells that migrated across MECs by upregulating PD-L1 expression on MECs. The susceptibility of rat pulmonary microvascular endothelial cells (RPMECs) to the H9N2 virus was evaluated by a plaque-forming assay and immunofluorescence staining. Then, we quantified the mRNA and protein levels of PD-L1 in RPMECs induced by H9N2 virus infection using quantitative real-time PCR and flow cytometry. The interaction between the activated T cells and RPMECs infected with the H9N2 virus was revealed using a coculture system. The effect of endothelial-derived PD-L1 on T cell function was investigated by using ELISA and flow cytometry with or without a PD-L1-specific antibody. Surface staining and the plaque-forming assay showed that the H9N2 virus infected and replicated in RPMECs. Both the PD-L1 mRNA level and PD-L1 protein level were upregulated in RPMECs infected with the H9N2 virus. H9N2 virus-induced PD-L1 expression significantly reduced the secretions of IL-2, IFN-γ and granzyme B and perforin expression in T cells. The above data were significantly increased after treatment with an anti-PD-L1 antibody, confirming the above mentioned findings. In addition, the induction of PD-L1 expression decreased the proliferative capacity of the cocultured T cells but did not affect the apoptosis rate of T cells. Taken together, the results suggest that the H9N2 virus is able to inhibit the T cell immune response by upregulating PD-L1 expression in pulmonary microvascular endothelial cells.
Sections du résumé
BACKGROUND
The PD-1/PD-L1 pathway is an inhibitory signaling pathway that maintains the balance between the immune response and immunotolerance, and its overactivation in cancer and viral infections inhibits T cell function. The target cells of various viruses, microvascular endothelial cells (MECs) have been shown to be key regulatory points in immune regulation and virion diffusion in vivo during infection with multiple influenza virus subtypes. Furthermore, avian influenza virus (AIV) infection can induce immunosuppression by causing imbalances in immune responses and immune organ damage. Thus, the aim of this study was to investigate whether the H9N2 virus inhibited the immune function of T cells that migrated across MECs by upregulating PD-L1 expression on MECs.
METHODS
The susceptibility of rat pulmonary microvascular endothelial cells (RPMECs) to the H9N2 virus was evaluated by a plaque-forming assay and immunofluorescence staining. Then, we quantified the mRNA and protein levels of PD-L1 in RPMECs induced by H9N2 virus infection using quantitative real-time PCR and flow cytometry. The interaction between the activated T cells and RPMECs infected with the H9N2 virus was revealed using a coculture system. The effect of endothelial-derived PD-L1 on T cell function was investigated by using ELISA and flow cytometry with or without a PD-L1-specific antibody.
RESULTS
Surface staining and the plaque-forming assay showed that the H9N2 virus infected and replicated in RPMECs. Both the PD-L1 mRNA level and PD-L1 protein level were upregulated in RPMECs infected with the H9N2 virus. H9N2 virus-induced PD-L1 expression significantly reduced the secretions of IL-2, IFN-γ and granzyme B and perforin expression in T cells. The above data were significantly increased after treatment with an anti-PD-L1 antibody, confirming the above mentioned findings. In addition, the induction of PD-L1 expression decreased the proliferative capacity of the cocultured T cells but did not affect the apoptosis rate of T cells.
CONCLUSIONS
Taken together, the results suggest that the H9N2 virus is able to inhibit the T cell immune response by upregulating PD-L1 expression in pulmonary microvascular endothelial cells.
Identifiants
pubmed: 32631356
doi: 10.1186/s12985-020-01341-x
pii: 10.1186/s12985-020-01341-x
pmc: PMC7336647
doi:
Substances chimiques
B7-H1 Antigen
0
Tumor Necrosis Factor-alpha
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Références
Int J Mol Sci. 2017 Nov 14;18(11):
pubmed: 29135922
Mol Cells. 2018 Apr 30;41(4):271-281
pubmed: 29629559
Nature. 2013 Sep 26;501(7468):551-5
pubmed: 23842494
Scand J Immunol. 2017 Mar;85(3):175-181
pubmed: 28109025
Laryngoscope. 2018 Jan;128(1):E27-E32
pubmed: 28940446
Int J Clin Oncol. 2016 Jun;21(3):448-55
pubmed: 26864303
Virol J. 2015 Mar 01;12:34
pubmed: 25886647
Avian Pathol. 2003 Oct;32(5):551-60
pubmed: 14522712
Res Vet Sci. 2017 Dec;115:356-362
pubmed: 28692924
Virulence. 2013 Aug 15;4(6):537-42
pubmed: 23863601
Atherosclerosis. 2017 Apr;259:83-96
pubmed: 28340361
J Infect Dis. 2011 Jan 1;203(1):85-94
pubmed: 21148500
J Immunol. 2011 Jan 1;186(1):164-73
pubmed: 21106851
J Exp Clin Cancer Res. 2019 Sep 11;38(1):397
pubmed: 31506076
Cell. 2011 Sep 16;146(6):980-91
pubmed: 21925319
Vet Microbiol. 2015 Mar 23;176(1-2):88-96
pubmed: 25655813
Protein Cell. 2015 Jan;6(1):18-25
pubmed: 25384439
Virology. 2005 Sep 15;340(1):70-83
pubmed: 16026813
PLoS One. 2009 May 27;4(5):e5702
pubmed: 19479036
J Clin Microbiol. 2010 Mar;48(3):928-40
pubmed: 20089763
FASEB J. 2008 Mar;22(3):733-40
pubmed: 17925493
Emerg Microbes Infect. 2014 Dec;3(12):e88
pubmed: 26038507
Annu Rev Immunol. 2004;22:683-709
pubmed: 15032593
J Virol. 2015 Apr;89(8):4655-67
pubmed: 25673714
Cell Host Microbe. 2016 Dec 14;20(6):810-821
pubmed: 27916476
Diagn Pathol. 2016 Oct 8;11(1):95
pubmed: 27717372
J Immunol. 2002 Oct 1;169(7):3581-8
pubmed: 12244148
J Immunol Methods. 2000 Oct 20;244(1-2):205-15
pubmed: 11033033
PLoS Pathog. 2015 Dec 18;11(12):e1005364
pubmed: 26684741
J Infect Dis. 2006 Feb 1;193(3):404-12
pubmed: 16388488
J Biol Chem. 2004 Oct 22;279(43):45194-207
pubmed: 15308637
J Immunol. 2015 Aug 1;195(3):1054-63
pubmed: 26116499
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Front Immunol. 2017 Jan 12;7:684
pubmed: 28127298
J Virol. 2000 Dec;74(24):11825-31
pubmed: 11090182
Respir Res. 2007 Oct 25;8:73
pubmed: 17961210
Chin Med J (Engl). 2017 Apr 20;130(8):986-992
pubmed: 28397730
Curr Opin Virol. 2014 Aug;7:134-40
pubmed: 25063986
Annu Rev Pathol. 2006;1:171-98
pubmed: 18039112